Aker BioMarine ASA (FRA:1PG) Total Liabilities: €226.6 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1PG Aker BioMarine ASA FRA:1PG
63 GF Score
Price €9.79
GF Value €6.45
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Aker BioMarine ASA Total Liabilities?

Aker BioMarine ASA FRA:1PG +6.12% 63 Total Liabilities is €226.6 Mil as of Jun. 2026. GuruFocus rates FRA:1PG with a GF Score™ of 63/100 and a GF Value™ of €6.45 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Aker BioMarine ASA's Total Liabilities for the quarter that ended in Jun. 2026 was €226.6 Mil.

Aker BioMarine ASA's quarterly Total Liabilities increased from Jun. 2025 (€205.83 Mil) to Dec. 2025 (€209.23 Mil) and increased from Dec. 2025 (€209.23 Mil) to Jun. 2026 (€226.64 Mil).

Aker BioMarine ASA's annual Total Liabilities declined from Dec. 2023 (€422.37 Mil) to Dec. 2024 (€203.89 Mil) but then increased from Dec. 2024 (€203.89 Mil) to Dec. 2025 (€209.23 Mil).

Aker BioMarine ASA Total Liabilities Historical Data

* Premium members only.

The historical data trend for Aker BioMarine ASA's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aker BioMarine ASA Total Liabilities Chart

Aker BioMarine ASA Annual Data
Trend Dec11 Dec12 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 342.58 418.85 422.37 203.89 209.23

Aker BioMarine ASA Semi-Annual Data
Dec10 Jun11 Dec11 Jun12 Dec12 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 422.32 203.89 205.83 209.23 226.64
FRA:1PG
63GF Score
Aker BioMarine ASA FRA:1PG
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aker BioMarine ASA Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aker BioMarine ASA's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=65.929+(136.042+7.259
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=209.2

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=332.121-122.891
=209.2

Aker BioMarine ASA's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=68.485+(154.157+3.993
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=226.6

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=344.596-117.961
=226.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €226.6 Mil mean?
Aker BioMarine ASA (FRA:1PG) has a Total Liabilities of €226.6 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aker BioMarine ASA and its competitors.
Is Aker BioMarine ASA's Total Liabilities too high?
Aker BioMarine ASA's current Total Liabilities is €226.6 Mil. Overall, Aker BioMarine ASA has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aker BioMarine ASA's Total Liabilities compare to KHC and GIS?
Aker BioMarine ASA's Total Liabilities of €226.6 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Consumer Packaged Goods company?
A good Total Liabilities depends on the Consumer Packaged Goods industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aker BioMarine ASA and its competitors. Aker BioMarine ASA's current Total Liabilities is €226.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aker BioMarine ASA stock overvalued right now?
Based on GuruFocus' analysis, Aker BioMarine ASA (FRA:1PG) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.45, compared to a current price of €9.79 — trading 51.8% above its estimated fair value. The current Total Liabilities is €226.6 Mil. Aker BioMarine ASA's overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Aker BioMarine ASA (FRA:1PG), the current Total Liabilities is €226.6 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aker BioMarine ASA (FRA:1PG) Overvalued in 2026?

Based on GuruFocus' analysis, Aker BioMarine ASA stock appears to be overvalued. The current stock price of €9.79 is trading 51.8% above its estimated GF Value™ of €6.45. GuruFocus considers Aker BioMarine ASA to be Significantly Overvalued.

Key valuation signals for FRA:1PG:

  • Total Liabilities: €226.6 Mil
  • GF Value™: €6.45 vs. price of €9.79 (51.8% above fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the FRA:1PG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aker BioMarine ASA Business Description

Address Oksenoyveien 10, Lysaker, NOR, 1366
Aker BioMarine ASA is a supplier of krill-derived products, with a fully owned supply chain. The operations of the company span from harvesting krill in Antarctica with vessels owned by the company including distribution from Uruguay, and further processing of the krill into oil products in the United States. The segments of the company include Human Health Ingredients, Consumer Health Products, and Emerging Businesses. The company generates the majority of its revenue from the Human Health Ingredients segment, which includes Superba, Lysoveta, PL+ Algae, and the company's Houston manufacturing plant. The segment sells B2B krill oil supplements to nutritional brands for humans around the world.
63GF Score

Get the complete analysis for FRA:1PG

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.79
Price
€6.45
GF Value